Last updated: 11/03/2018 11:23:28

A study in elderly subjects with pneumonia to support the development of bacteriological diagnostic assays

GSK study ID
111074
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A study to collect blood and urine samples in elderly subjects with pneumonia to support the development of bacteriological diagnostic assays
Trial description: GSK Biologicals is working on the development of a vaccine to protect elderly people from bacterial pneumonia. Diagnostic of bacterial pneumonia is difficult, and for the future studies in that project, it would be useful to have some easy non invasive tests. New clinical read-outs are needed to detect and identify the causative pathogen. These assays will be based on specific antigen detection in the urine or specific pathogen DNA detection in the blood. Technical and clinical validation of these assays will be realised at later stage with samples coming from epidemiological and/or phase III studies.
To allow the development of such tests in GSK Biologicals laboratories, urine and blood samples are needed from subjects aged 65 or above who have diagnosed pneumonia.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Detection of Streptococcus pneumoniae antigens in the urine of subjects with diagnosed pneumonia.

Timeframe: At the time of analysis.

Detection of Streptococcus pneumoniae DNA in the blood of subjects with diagnosed pneumonia.

Timeframe: At the time of analysis.

Secondary outcomes:

Detection of Non-Typable Haemophilus influenzae antigens in the urine of subjects with diagnosed pneumonia.

Timeframe: At the time of analysis.

Detection of Non-Typable Haemophilus influenzae DNA in the blood of subjects with diagnosed pneumonia.

Timeframe: At the time of analysis.

Interventions:
Procedure/surgery: Blood sample
Procedure/surgery: Urine sample
Enrollment:
21
Observational study model:
Case-Only
Primary completion date:
2009-09-02
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Infections, Streptococcal
Product
GSK324332A
Collaborators
Not applicable
Study date(s)
March 2008 to February 2009
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
65+ years
Accepts healthy volunteers
No
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female aged 65 or above at the time of the study.
  • Vaccination with a pneumococcal or Haemophilus vaccine within the last 3 months before study entry.
  • Antibiotherapy started more than 7 days before Screening.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Yvoir, Belgium, 5330
Status
Study Complete
Location
GSK Investigational Site
Brussels, Belgium, 1200
Status
Study Complete

Study documents

No study documents available.

Results overview

No study documents available

Recruitment status
Finalized
Actual primary completion date
2009-09-02
Actual study completion date
2009-09-02

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website